Key takeaway: Management reported that Acutaas Chemicals Limited began the financial year on a challenging note due to geopolitical tensions but managed to secure raw material availability and maintain supply continuity. The company achieved strong revenue of INR 329.7 crores, reflecting a year-on-year growth of 59.1%. Demand for battery chemicals remained exceptionally strong, with the successful completion of trial runs for the battery chemicals plant. Management highlighted a robust performance in the Advanced Pharmaceutical Intermediates segment, with revenue growth of 76.5%. The Specialty Chemicals segment saw a decline in commodity chemicals revenue, which management anticipated would be offset by growth in battery chemicals and new specialty products. Management set a goal of 25% revenue growth for the full year with stable margins. The earnings call concluded with management expressing confidence in the company's growth trajectory and operational efficiencies.

Key takeaway: The investor presentation from Acutaas Chemicals Limited reported strong financial performance for the first quarter of FY27, with revenue from operations increasing by 59.1% year-over-year to ₹3,297 million. EBITDA rose by 122.1% to ₹1,131 million, and profit after tax (PAT) grew by 70.4% to ₹750 million. Management highlighted the agility of their business model and the successful delivery to customers. The company received recognition as a Great Place to Work and obtained the Responsible Care certification from the Indian Chemical Council, emphasizing their commitment to safety and sustainability. Management set a goal of achieving 25% revenue growth for the full year while maintaining stable margins. The presentation included detailed financial metrics and trends, showcasing growth across various business segments.

Key takeaway: The investor presentation from Acutaas Chemicals Limited, dated May 16, 2026, outlines the company's business operations, growth trajectory, and financial performance. Management reported a significant global market share in key intermediates, with capabilities to manufacture up to N-1 stages and over 90% of products being backward integrated to basic chemicals. The company highlighted its unique position as the only manufacturer of photoresist chemicals in India and its expansion into markets such as Japan, South Korea, and Taiwan. Financially, Acutaas achieved revenues of ₹11,741 million for FY26, with a focus on advanced pharmaceutical intermediates and specialty chemicals. The presentation also detailed ongoing capital expenditures for capacity expansion and sustainability initiatives, including a strong emphasis on R&D and environmental stewardship. The company reported a diverse customer base and a commitment to innovation across various chemical sectors.

Key takeaway: Acutaas Chemicals Limited held its Q4 FY26 earnings conference call on April 30, 2026, where management provided insights into the company's performance and strategic initiatives. Chairman Naresh Patel reported a strong financial year, with revenues reaching INR1,339 crores and a PAT of INR356 crores, reflecting a growth trajectory. He noted challenges in the chemical industry due to geopolitical tensions affecting supply chains but emphasized robust demand for their products. The company is advancing in its battery chemicals and semiconductor segments, with plans to commercialize additional products in FY27. Vice President Abhishek Patel highlighted a 43.9% year-on-year growth in the Advanced Pharmaceutical Intermediates segment and a steady performance in Specialty Chemicals. CFO Bhavin Shah detailed financial metrics, including a 40.3% revenue growth for the quarter. Management set a goal of 25% revenue growth for FY27, supported by long-term contracts and a diversified product portfolio.

Key takeaway: Acutaas Chemicals Limited reported strong financial results for Q4 FY26, with revenue from operations reaching ₹4,328 million, a year-on-year increase of 40.3%. EBITDA for the quarter was ₹1,835 million, reflecting a 116.0% increase, while PAT stood at ₹1,343 million, up 114.1% year-on-year. Management highlighted a strategic focus on diversifying its chemicals business across three high-growth verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. The company achieved its highest-ever PAT margin of 31.0% in Q4 FY26. For FY26, total revenue from operations was ₹13,394 million, a 33.0% increase from the previous year, with PAT more than doubling to ₹3,564 million. Management expressed confidence in entering FY27 from a position of strength, setting a goal of 25% revenue growth for the upcoming year.

Key takeaway: Acutaas Chemicals Limited held its Q3 FY26 earnings conference call on January 28, 2026, where management provided updates on the company's strategic initiatives and financial performance. Chairman Naresh Patel reported that the company is evolving into a diversified chemicals firm with multiple business verticals, including pharmaceutical intermediates, battery chemicals, and semiconductor chemicals. The company inaugurated a new block for battery chemicals and anticipates significant ramp-up in this segment from Q1 FY27. The pharmaceutical intermediates segment achieved a revenue of INR351.1 crores, reflecting a 47% year-on-year growth. Management revised revenue guidance for FY26 upwards to approximately 30% growth, with profit after tax surpassing INR100 crores for the quarter. CFO Bhavin Shah highlighted a gross margin expansion to 57% and a PAT margin of 27%. The call concluded with management expressing confidence in the company's growth trajectory and commitment to innovation.